Ab­b­Vie seals $63B deal to buy a trou­bled Al­ler­gan — spelling out $1B in R&D cuts

Brent Saun­ders has found his way out of the cur­rent fix he’s in at Al­ler­gan $AGN. He’s sell­ing the com­pa­ny to Ab­b­Vie for $63 bil­lion in the lat­est ex­am­ple of the hot M&A mar­ket in bio­phar­ma.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN